Funding Cuts Threaten Alzheimer’s Research in Pittsburgh

Recent funding cuts from the Trump administration may derail critical research on Alzheimer’s disease risk among 600 older adults. Researchers are facing the possibility of shutting down their study without sharing the findings of cognitive tests with the participants, even though all the data is ready to be analyzed.

In August, the administration canceled a federal research grant aimed at two low-income, predominantly Black neighborhoods in Pittsburgh. Researchers were instructed to halt the study in just 90 days, which is over five months earlier than originally planned. Consequently, they now find themselves without the necessary time or resources to analyze the data gathered from the trial participants.

This cut in funding could lead to significant delays in diagnosing Alzheimer’s disease or related conditions within this group, where early diagnosis is vital for effective treatment.

According to Grant Witness, which monitors funding changes, the Trump administration has disrupted over 5,700 NIH-funded medical research grants in the last two years. While more than 4,500 of these have been reinstated, the cancellation of clinical trials has affected over 74,000 participants nationwide, according to a Jama study. Various fields, including childhood hearing loss and pain management during cesarean sections, have been impacted by these cuts.

These funding reductions form part of the administration’s broader attempt to reshape federal science funding according to its agenda, often justified by criticisms of diversity, equity, and inclusion (DEI) initiatives.

The researchers at the University of Pittsburgh have also become plaintiffs in a class-action lawsuit against the NIH. They assert that the administration is stifling research with outcomes it doesn’t favor.

Olga Akselrod, a senior counsel with the ACLU’s racial justice program and a lead litigator in the case, stressed that the consequences of censoring research can be dire. “It’s risky for public health when research is filtered through political biases, especially studies targeting underserved groups experiencing significant health disparities,” she stated.

The canceled study, led by Tamara Dubowitz and Andrea Rosso, focused on the environmental factors contributing to Alzheimer’s risk in historically red-lined neighborhoods, which have long been denied equitable access to resources. Black Americans are at a higher risk of developing Alzheimer’s compared to their white counterparts, yet they are underrepresented in research — a fact that underscores the uneven landscape of medical studies.

Experts point out that the administration’s interpretation of DEI is confusing and conflates it with health equity, which is relevant to the Pittsburgh study grant.

Notable figures have voiced concerns that the funding cancellations could have life-threatening implications for Americans. In the case of Alzheimer’s, early diagnosis is crucial, and once diagnosed, there’s currently no cure; treatments available to slow the progression of the disease work best if implemented earlier.

Roderick Blair, a participant in the study, expressed that the grant cancellation feels like a targeted response for investigating the connections between health issues faced by Black Americans and systemic racism. “If you don’t align with their views, you’re going to face consequences,” he remarked, reflecting on the wider implications of such a political stance.

The study aimed to track cognitive decline over an 18-month to two-year period. Participants underwent intensive cognitive assessments, some lasting hours and involving sensitive questions about their past.

When the grant was cut, data collection had just wrapped up, and researchers were gearing up for a “cognitive status adjudication” to analyze the tests. This process would involve specialists, but access to such experts is in high demand, often leading to long waits for patients. Over the past five years, the federal government invested more than $10 million in this study.

Results from the study were promised to participants upon their consent, but delivering on those results within the time constraints now presented seems unfeasible. Researchers had hoped for a one-year cost-free extension, as funding had been frozen for several months during the course of the study due to associated upheaval over DEI initiatives. The University of Pittsburgh is appealing the cancellation.

According to Jared Stonesifer, the University’s communications head, they are actively pursuing appeals regarding the NIH’s termination of these awards. He believes that their case is strong and expresses hope for a positive outcome.

Dubowitz indicated that the appeal includes a request to provide results to participants, which she sees as an essential part of a responsible study conclusion. However, it’s unclear if the NIH will agree on this point.

The government has maintained that the grant “no longer achieves the program goals or agency priorities” and argued the study lacks specific, measurable outcomes that align with NIH’s focus.

Beginning in 2025, numerous scientific grants were canceled, but many have been reinstated following legal challenges. Nonetheless, the administration continues to cancel additional research funding into 2026, including significant Alzheimer’s grants at Pittsburgh and Emory University.

Legal experts believe these strategic cancellations may serve as test cases for future court decisions. This effort coincides with the administration’s pursuit of higher political control over the $1 trillion federal grant system.

Reflecting on his experience, Blair noted, “The most valuable aspect researchers offered was trust. They kept you informed about progress and areas for improvement.”